Adimab Provides Year-End Update on 2022 Partnership Activities


Lebanon, NH–(business wire)–Adimab, LLC, a global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced that it has entered into 11 new partnership agreements for 2022. 52 technology and development milestones achieved through partnerships and numerous collaborations.

To date, Adimab has partnered with more than 105 companies to discover treatment programs. New partnerships for 2022 include collaborations with Alnylam, DEM BioPharma, Related Sciences, Ridgeline Discovery, Santa Ana Bio, Inc., Solve Therapeutics, Inc., Stanford, Vertex and more. In addition, Adimab has expanded partnerships with Biogen, Bioceus, Bristol-Myers Squibb, Invivid, Link ImmunoTherapeutics, Regeneron, Surface Oncology and Werewolf.

In 2022, Adimab and its partners will initiate the discovery of 57 new treatment programs, bringing the total number of royalty-bearing programs launched to over 475. Many partners have contractual rights to initiate programs with Adimab in the future with additional royalties.

Guy Van Meter, Adimab’s Chief Business Officer, said: “Our partner-oriented approach to collaboration, along with our strong suite of existing and new technology offerings, has led to a substantial stream of new partnerships and regular expansion with our current partners.”

“At Adimab, we know that quality is the number one driver that enables us to bring highly competitive programs to clinics and markets. We generate antibodies and other proteins with the best developability profiles and enable our partners to succeed with these molecules.” As we expand into therapeutics, cell-based therapies, and other complex molecules, we face increasingly high hurdles to clinical, regulatory, and commercial success.We continue to listen to our partners. , developing new approaches and solutions to ensure that work with these more challenging modalities meets the quality standards for which Adimab has become well known.”

technology:

Antibody Discovery: Adimab discovers therapeutic antibodies in IgG and single domain formats through proprietary yeast-based technology. Adimab not only has its full human synthetic diversity, but also live sauce. Antibodies from Adimab have excellent specificity and have been utilized as monospecific and bispecific therapies, as well as CAR-T, ADC, and other modalities.

engineering: Adimab has developed and refined its engineering capabilities through thousands of lead antibody optimization efforts. The process begins with one or more lead antibodies selected by the partner with the aim of optimizing potency, specificity and/or developability. These leads may come from Adimab’s discovery process or from external sources. It is commonly used to modify undesirable properties of antibodies. live and phage-based technology. Adimab also applies its engineering expertise to cytokines, TCRs, and other modalities.

Bispecific and T cell engagers: Adimab has extensive bispecific and multispecific capabilities, including general light chain and fragment-based discovery and engineering. Additionally, Adimab has unique solutions for both Fc (HC:HC) and Fab (HC:LC) heterodimerization, providing numerous bispecific and multispecific Enables product design generation. These are commonly combined with Adimab’s highly characterized series of CD3 antibodies to generate bispecific and multispecific T cell engagers.

Complex target workflow: Certain membrane-dependent proteins (eg, GPCRs and ion channels) do not function well outside their native membrane environment.For these targets, Adimab has developed a proprietary in vitro When live A discovery workflow that relies only on native membrane-expressed targets and does not require antigen mimics. The company has employed these workflows many times to generate robust panels of specific antibodies against these classically challenging targets.

About Azimab

Adimab is a leading provider of therapeutic antibody discovery and engineering technology. This includes naive discovery from synthetic yeast or B-cell (mouse and human) libraries, antibody engineering and optimization, multispecific antibody engineering, and non-exclusively licensed for bispecific applications. Includes a portfolio of proprietary CD3 antibodies. Adimab is solely focused on partners rather than developing an internal product pipeline. Since 2009, Adimab has partnered with over 105 pharmaceutical and biotechnology companies, resulting in over 475 therapeutic programs, over 60 clinical programs and the first approved products. Adimab’s technology has been transferred and implemented by Biogen, GSK, Lilly, Merck, Novo Nordisk and Takeda. Funded drug discovery partners include major pharmaceutical companies such as Boehringer Ingelheim, Bristol-Myers Squibb, Novartis, Regeneron, Sanofi and Takeda. Adimab is part of early stage venture backers such as Amagma, Dragonfly, iOmx, NextPoint, Pliant, Tizona and TRex Bio, as well as Alector, Cullinan Oncology, Innovent, Cullinan Oncology, Innovent, Jounce, Mersana, Scholar Rock and Surface Oncology.

Adimab’s integrated antibody discovery and engineering platform provides unprecedented speed from antigen to purified, full-length human IgG. Adimab offers a fundamental advantage by offering a diverse panel of therapeutically relevant antibodies that meet the most stringent criteria for affinity, epitope coverage, cross-species cross-reactivity and developability. Adimab enables partners to rapidly expand their biologics pipelines through a wide range of technology access arrangements. For more information, please visit http://www.adimab.com.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *